DE69934434D1 - Reinigung von polysaccharid-protein-konjugat impfstoffen durch ultrafiltration mit ammoniumsulfat-lösungen - Google Patents

Reinigung von polysaccharid-protein-konjugat impfstoffen durch ultrafiltration mit ammoniumsulfat-lösungen

Info

Publication number
DE69934434D1
DE69934434D1 DE69934434T DE69934434T DE69934434D1 DE 69934434 D1 DE69934434 D1 DE 69934434D1 DE 69934434 T DE69934434 T DE 69934434T DE 69934434 T DE69934434 T DE 69934434T DE 69934434 D1 DE69934434 D1 DE 69934434D1
Authority
DE
Germany
Prior art keywords
ultrafiltration
polysaccharide
purification
ammonium sulphate
protein conjugate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69934434T
Other languages
English (en)
Other versions
DE69934434T2 (de
Inventor
P Mcmaster
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Pasteur Ltd
Sanofi Pasteur Inc
Original Assignee
Connaught Laboratories Ltd
Connaught Laboratories Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Connaught Laboratories Ltd, Connaught Laboratories Inc filed Critical Connaught Laboratories Ltd
Application granted granted Critical
Publication of DE69934434D1 publication Critical patent/DE69934434D1/de
Publication of DE69934434T2 publication Critical patent/DE69934434T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/25—Chemistry: analytical and immunological testing including sample preparation
    • Y10T436/25375—Liberation or purification of sample or separation of material from a sample [e.g., filtering, centrifuging, etc.]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
DE69934434T 1998-12-29 1999-12-16 Reinigung von polysaccharid-protein-konjugat impfstoffen durch ultrafiltration mit ammoniumsulfat-lösungen Expired - Lifetime DE69934434T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/221,728 US6146902A (en) 1998-12-29 1998-12-29 Purification of polysaccharide-protein conjugate vaccines by ultrafiltration with ammonium sulfate solutions
US221728 1998-12-29
PCT/US1999/030109 WO2000038711A2 (en) 1998-12-29 1999-12-16 Purification of polysaccharide-protein conjugate vaccines by ultrafiltration with ammonium sulfate solutions

Publications (2)

Publication Number Publication Date
DE69934434D1 true DE69934434D1 (de) 2007-01-25
DE69934434T2 DE69934434T2 (de) 2008-01-03

Family

ID=22829099

Family Applications (3)

Application Number Title Priority Date Filing Date
DE06025470T Pending DE06025470T1 (de) 1998-12-29 1999-12-16 Reinigung von Polysaccharid-Protein-Konjugat Impfstoffen durch Ultrafiltration mit Ammoniumsulfat-Lösungen
DE69943169T Expired - Lifetime DE69943169D1 (de) 1998-12-29 1999-12-16 Reinigung von Polysaccharid-Protein-Konjugat Impfstoffen durch Ultrafiltration mit Ammoniumsulfat-Lösungen
DE69934434T Expired - Lifetime DE69934434T2 (de) 1998-12-29 1999-12-16 Reinigung von polysaccharid-protein-konjugat impfstoffen durch ultrafiltration mit ammoniumsulfat-lösungen

Family Applications Before (2)

Application Number Title Priority Date Filing Date
DE06025470T Pending DE06025470T1 (de) 1998-12-29 1999-12-16 Reinigung von Polysaccharid-Protein-Konjugat Impfstoffen durch Ultrafiltration mit Ammoniumsulfat-Lösungen
DE69943169T Expired - Lifetime DE69943169D1 (de) 1998-12-29 1999-12-16 Reinigung von Polysaccharid-Protein-Konjugat Impfstoffen durch Ultrafiltration mit Ammoniumsulfat-Lösungen

Country Status (12)

Country Link
US (1) US6146902A (de)
EP (3) EP1140156B1 (de)
AT (2) ATE347906T1 (de)
AU (1) AU2367500A (de)
CA (2) CA2358022C (de)
CY (3) CY1105985T1 (de)
DE (3) DE06025470T1 (de)
DK (2) DK1140156T3 (de)
ES (2) ES2277462T3 (de)
HK (1) HK1106999A1 (de)
PT (2) PT1140156E (de)
WO (1) WO2000038711A2 (de)

Families Citing this family (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6248334B1 (en) * 1997-01-08 2001-06-19 Henry M. Jackson Foundation For The Advancement Of Military Medicine Process for preparing conjugate vaccines including free protein and the conjugate vaccines, immunogens, and immunogenic reagents produced by this process
TW574036B (en) * 1998-09-11 2004-02-01 Elan Pharm Inc Stable liquid compositions of botulinum toxin
PT1296715E (pt) * 2000-06-29 2012-01-19 Smithkline Beecham Biolog Composição vacinal multivalente
AU2002224414B2 (en) * 2000-10-18 2006-10-19 Clarity Technologies Incorporated Method and device for diluting a fluid and detecting analytes within a diluted fluid
EA006947B1 (ru) * 2001-01-23 2006-06-30 Авентис Пастер Поливалентная менингококковая полисахаридно-белковая конъюгированная вакцина
JP2004534527A (ja) 2001-04-04 2004-11-18 デーエスエム イーペー アセッツ ベスローテン フェンノートシャップ 精製ラクターゼ
GB0115176D0 (en) * 2001-06-20 2001-08-15 Chiron Spa Capular polysaccharide solubilisation and combination vaccines
WO2004032958A1 (en) 2002-10-11 2004-04-22 Chiron Srl Polypeptide-vaccines for broad protection against hypervirulent meningococcal lineages
GB0227346D0 (en) 2002-11-22 2002-12-31 Chiron Spa 741
WO2004067030A2 (en) 2003-01-30 2004-08-12 Chiron Srl Injectable vaccines against multiple meningococcal serogroups
WO2004103400A2 (en) 2003-05-07 2004-12-02 Aventis Pasteur,Inc. Multivalent meningococcal derivatized polysaccharide-protein conjugates and corresponding vaccines
CA2524853A1 (en) 2003-05-07 2005-01-20 Aventis Pasteur, Inc. Method of enhanced immunogenicity to meningococcal vaccination
CA2530364C (en) * 2003-06-23 2014-03-18 Baxter International Inc. Vaccines against group y neisseria meningitidis and meningococcal combinations thereof
CA2530434A1 (en) 2003-06-23 2005-01-06 Aventis Pasteur, Inc. Immunization method against neisseria meningitidis serogroups a and c
GB0323103D0 (en) 2003-10-02 2003-11-05 Chiron Srl De-acetylated saccharides
ATE506963T1 (de) 2003-10-02 2011-05-15 Novartis Vaccines & Diagnostic Kombinationsimpfstoffe gegen meningitis
EP1713508A2 (de) * 2004-01-29 2006-10-25 Biosynexus Incorporated Verwendung von aminoox-funktionalen gruppen bei der herstellung von vakzine-konjugaten
GB0408977D0 (en) 2004-04-22 2004-05-26 Chiron Srl Immunising against meningococcal serogroup Y using proteins
EP2351582A1 (de) * 2004-08-30 2011-08-03 Sanofi Pasteur, Inc. Mehrwertige derivatisierte meningokokkale Polysaccharidproteinkonjugate und Vakzine
KR20070095868A (ko) * 2004-09-21 2007-10-01 사노피 파스퇴르 인크 다가 수막구균 유도체화된 다당류-단백질 접합체 및 백신
GB0502095D0 (en) 2005-02-01 2005-03-09 Chiron Srl Conjugation of streptococcal capsular saccharides
GB0502096D0 (en) 2005-02-01 2005-03-09 Chiron Srl Purification of streptococcal capsular polysaccharide
KR101408113B1 (ko) 2005-06-27 2014-06-16 글락소스미스클라인 바이오로지칼즈 에스.에이. 백신 제조 방법
GB0513852D0 (en) * 2005-07-06 2005-08-10 Celltech R&D Ltd Biological products
GB0524066D0 (en) 2005-11-25 2006-01-04 Chiron Srl 741 ii
NZ572054A (en) 2006-03-22 2011-12-22 Novartis Ag Regimens for immunisation with meningococcal conjugates
GB0605757D0 (en) * 2006-03-22 2006-05-03 Chiron Srl Separation of conjugated and unconjugated components
US10828361B2 (en) * 2006-03-22 2020-11-10 Glaxosmithkline Biologicals Sa Regimens for immunisation with meningococcal conjugates
AU2007293673B2 (en) 2006-09-07 2013-06-27 Glaxosmithkline Biologicals S.A. Vaccine
GB0700562D0 (en) 2007-01-11 2007-02-21 Novartis Vaccines & Diagnostic Modified Saccharides
HUE039169T2 (hu) 2007-03-23 2018-12-28 Wyeth Llc Rövidített tisztítási eljárás Streptococcus pneumoniae tok-poliszacharidok elõállítására
EP2142211A1 (de) 2007-05-02 2010-01-13 GlaxoSmithKline Biologicals S.A. Impfstoff
GB0713880D0 (en) 2007-07-17 2007-08-29 Novartis Ag Conjugate purification
GB0818453D0 (en) 2008-10-08 2008-11-12 Novartis Ag Fermentation processes for cultivating streptococci and purification processes for obtaining cps therefrom
ES2586308T3 (es) 2008-10-27 2016-10-13 Glaxosmithkline Biologicals Sa Procedimiento de purificación de un hidrato de carbono de Streptococcus del grupo A
GB0822634D0 (en) 2008-12-11 2009-01-21 Novartis Ag Meningitis vaccines
GB0822633D0 (en) 2008-12-11 2009-01-21 Novartis Ag Formulation
KR20110091546A (ko) * 2008-12-18 2011-08-11 와이어쓰 엘엘씨 스트렙토코커스 뉴모니에 혈청형 19ａ 폴리사카라이드 분자량을 조절하는 방법
AU2009335824B2 (en) * 2008-12-18 2013-07-04 Wyeth Llc Method for controlling Streptococcus pneumoniae polysaccharide molecular weight using carbon
WO2010151544A1 (en) 2009-06-22 2010-12-29 Wyeth Llc Immunogenic compositions of staphylococcus aureus antigens
JP2012530785A (ja) 2009-06-22 2012-12-06 ワイス・エルエルシー 組成物および黄色ブドウ球菌（Ｓｔａｐｈｙｌｏｃｏｃｃｕｓａｕｒｅｕｓ）血清型５および８莢膜多糖コンジュゲート免疫原性組成物を調製するための方法
WO2011017101A2 (en) 2009-07-27 2011-02-10 Fina Biosolutions, Llc Method for producing protein-carbohydrate vaccines reduced in free carbohydrate
CA2779798C (en) 2009-09-30 2019-03-19 Novartis Ag Conjugation of staphylococcus aureus type 5 and type 8 capsular polysaccharides
JP5914344B2 (ja) 2009-10-30 2016-05-11 ノバルティス アーゲー Ｓｔａｐｈｙｌｏｃｏｃｃｕｓａｕｒｅｕｓ５型および８型の莢膜糖の精製
US8105843B2 (en) * 2009-11-04 2012-01-31 Buchanan Thomas M Methods and devices to enhance sensitivity and evaluate sample adequacy and reagent reactivity in rapid lateral flow immunoassays
WO2011084705A2 (en) 2009-12-17 2011-07-14 Fina Biosolutions, Llc Chemical reagents for the activation of polysaccharides in the preparation of conjugate vaccines
WO2011080595A2 (en) 2009-12-30 2011-07-07 Novartis Ag Polysaccharide immunogens conjugated to e. coli carrier proteins
NZ602971A (en) 2010-04-23 2014-11-28 Serum Inst India Ltd Simple method for simultaneous removal of multiple impurities from culture supernatants to ultralow levels
GB201101665D0 (en) 2011-01-31 2011-03-16 Novartis Ag Immunogenic compositions
EP2655389A2 (de) 2010-12-24 2013-10-30 Novartis AG Verbindungen
WO2013038375A2 (en) 2011-09-14 2013-03-21 Novartis Ag Methods for making saccharide-protein glycoconjugates
US20140234360A1 (en) 2011-09-30 2014-08-21 The United States of America, as represented by the Secretary, Dept.of Health and Human Services Influenza vaccine
AU2012335208B2 (en) 2011-11-07 2017-08-31 Glaxosmithkline Biologicals S.A. Carrier molecule comprising a spr0096 and a spr2021 antigen
JP2015518845A (ja) 2012-05-22 2015-07-06 ノバルティス アーゲー 髄膜炎菌血清群ｘコンジュゲート
EA201590427A1 (ru) 2012-10-02 2015-09-30 Глаксосмитклайн Байолоджикалс С.А. Нелинейные сахаридные конъюгаты
US9855324B2 (en) 2012-10-03 2018-01-02 Glaxosmithkline Biologicals Sa Immunogenic compositions
US11708411B2 (en) 2013-12-20 2023-07-25 Wake Forest University Health Sciences Methods and compositions for increasing protective antibody levels induced by pneumococcal polysaccharide vaccines
CN104387491B (zh) * 2014-11-25 2017-12-05 中国医学科学院医学生物学研究所 一种b型流感嗜血杆菌荚膜多糖的制备方法
EP3439704A1 (de) 2016-04-05 2019-02-13 GSK Vaccines S.r.l. Immunogene zusammensetzungen
MX2019002489A (es) 2016-09-02 2019-10-21 Sanofi Pasteur Inc Vacuna contra neisseria meningitidis.
US11602559B2 (en) 2016-10-03 2023-03-14 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services HIV-1 Env fusion peptide immunogens and their use
WO2018081832A1 (en) 2016-10-31 2018-05-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Peptide fragments from filoviruses and their uses
US20210108002A1 (en) 2016-12-06 2021-04-15 Glaxosmithkline Biologicals Sa Purification Process For Capsular Polysaccharide
US20200222550A1 (en) * 2017-01-31 2020-07-16 Merck Sharp & Dohme Corp. Methods for production of capsular polysaccharide protein conjugates from streptococcus pneumoniae serotype 19f
CN111093650B (zh) 2017-09-07 2024-03-01 默沙东有限责任公司 肺炎球菌多糖及其在免疫原性多糖-载体蛋白缀合物中的用途
GEP20227420B (en) 2017-12-06 2022-10-10 Merck Sharp & Dohme Llc Compositions comprising streptococcus pneumoniae polysaccharide-protein conjugates and methods of use thereof
US11896656B2 (en) 2018-04-30 2024-02-13 Merck Sharp & Dohme Llc Methods for providing a homogenous solution of lyophilized mutant diptheria toxin in dimethylsulfoxide
EP3787673A4 (de) 2018-04-30 2022-04-27 Merck Sharp & Dohme Corp. Verfahren zur herstellung von kapsulären streptococcus-pneumoniae-polysaccharid-trägerproteinkonjugaten
US20210353740A1 (en) 2018-09-23 2021-11-18 The United States Of America, As Represented By The Secretary, Department Of Health And Human Servic Hiv-1 env fusion peptide nanoparticle carrier conjugates and their use
JOP20210148A1 (ar) 2018-12-19 2023-01-30 Merck Sharp & Dohme تركيبات تشتمل على متقارنات بولي سكاريد-بروتين للمكورات العقدية الرئوية وطرق استخدامها
CA3139257A1 (en) 2019-05-10 2020-11-19 Glaxosmithkline Biologicals Sa Conjugate production
JP2023529925A (ja) 2020-06-12 2023-07-12 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム ナノ粒子ワクチンを使用する細菌免疫化
CN116847879A (zh) 2020-11-13 2023-10-03 葛兰素史密丝克莱恩生物有限公司 细菌蛋白载体和缀合方法
TW202245835A (zh) 2021-02-04 2022-12-01 美商默沙東有限責任公司 用於肺炎球菌結合物疫苗之奈米乳化液佐劑組合物
WO2022182388A1 (en) * 2021-02-26 2022-09-01 The Penn State Research Foundation Separation apparatus and method
WO2023111826A1 (en) 2021-12-14 2023-06-22 Glaxosmithkline Biologicals Sa Bacterial immunization using qbeta hairpin nanoparticle constructs
WO2023200704A1 (en) 2022-04-11 2023-10-19 Sanofi Pasteur Inc. Protein-saccharide conjugation with sodium cyanoborohydride

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4459286A (en) * 1983-01-31 1984-07-10 Merck & Co., Inc. Coupled H. influenzae type B vaccine
US4456691A (en) * 1983-02-28 1984-06-26 Suad Stark Antigen for PCB, antibody raised by same, and method of making same
NZ214503A (en) * 1984-12-20 1990-02-26 Merck & Co Inc Covalently-modified neutral bacterial polysaccharides, stable covalent conjugates of such polysaccharides and immunogenic proteins, and methods of preparing such polysaccharides and conjugates
US4780409A (en) * 1985-05-02 1988-10-25 Genetic Systems Corporation Thermally induced phase separation immunoassay
JPH0643336B2 (ja) * 1988-06-30 1994-06-08 呉羽化学工業株式会社 血管増殖抑制剤
US5122614A (en) * 1989-04-19 1992-06-16 Enzon, Inc. Active carbonates of polyalkylene oxides for modification of polypeptides
NZ239643A (en) * 1990-09-17 1996-05-28 North American Vaccine Inc Vaccine containing bacterial polysaccharide protein conjugate and adjuvant (c-nd-che-a-co-b-r) with a long chain alkyl group.
US5153312A (en) * 1990-09-28 1992-10-06 American Cyanamid Company Oligosaccharide conjugate vaccines
CA2059692C (en) * 1991-01-28 2004-11-16 Peter J. Kniskern Pneumoccoccal polysaccharide conjugate vaccine
AU1140495A (en) * 1994-01-27 1995-08-03 Bristol-Myers Squibb Company Method for preparing thioether conjugates
SE9601158D0 (sv) * 1996-03-26 1996-03-26 Stefan Svenson Method of producing immunogenic products and vaccines
FR2748476B1 (fr) * 1996-05-07 1998-08-14 Pf Medicament Complexe immunogene, son utilisation, son procede de preparation et vaccin le contenant
US6248334B1 (en) * 1997-01-08 2001-06-19 Henry M. Jackson Foundation For The Advancement Of Military Medicine Process for preparing conjugate vaccines including free protein and the conjugate vaccines, immunogens, and immunogenic reagents produced by this process
US5965714A (en) * 1997-10-02 1999-10-12 Connaught Laboratories, Inc. Method for the covalent attachment of polysaccharides to protein molecules

Also Published As

Publication number Publication date
EP1762245B1 (de) 2011-01-26
CA2358022C (en) 2008-03-11
US6146902A (en) 2000-11-14
EP1762245A2 (de) 2007-03-14
CA2621097A1 (en) 2000-07-06
WO2000038711A3 (en) 2000-10-19
CY1105985T1 (el) 2011-04-06
EP1140156A2 (de) 2001-10-10
ES2278551T1 (es) 2007-08-16
CY1111375T1 (el) 2015-08-05
EP2292261A1 (de) 2011-03-09
DE69943169D1 (de) 2011-03-10
CA2358022A1 (en) 2000-07-06
PT1140156E (pt) 2007-02-28
ES2277462T3 (es) 2007-07-01
EP1140156B1 (de) 2006-12-13
DE69934434T2 (de) 2008-01-03
AU2367500A (en) 2000-07-31
ATE347906T1 (de) 2007-01-15
DK1762245T3 (da) 2011-04-04
EP1762245A3 (de) 2007-04-25
ES2278551T3 (es) 2011-04-11
ATE496633T1 (de) 2011-02-15
DK1140156T3 (da) 2007-03-26
PT1762245E (pt) 2011-05-02
WO2000038711A2 (en) 2000-07-06
CY2200152T2 (el) 2010-07-28
HK1106999A1 (en) 2008-03-28
DE06025470T1 (de) 2007-08-02

Similar Documents

Publication Publication Date Title
DE69934434D1 (de) Reinigung von polysaccharid-protein-konjugat impfstoffen durch ultrafiltration mit ammoniumsulfat-lösungen
ATE321146T1 (de) Methoden zur modifikation von kohlenhydratanteilen
DK0665013T3 (da) Behandling af hyperproliferative karsygdomme
DE59100581D1 (de) Verfahren zur herstellung von torfersatz, anlage zur durchführung dieses verfahrens, anwendung des verfahrens und nach diesem verfahren hergestellter torfersatz.
BR0108353A (pt) Método de filtração de fluxo proveniente de laticìnios
DE69518843D1 (de) Topologische korrektur von getriebezähnen durch balligkeit
TR200200205T2 (tr) MEK inhibitörleri kullanılarak kronik ağrının tedavi edilmesi
DE60026844D1 (de) Verfahren zur herstellung von 3,3-dimethylbutanal
ATE220560T1 (de) Eisen-dextran verbindung zur verwendung als komponente in einer therapeutischen zusammensetzung zur behandlung oder prophylaxe von eisenmangel, sowie verfahren zur herstellung der eisen-dextran verbindung und ihre anwendung zur herstellung einer parenteral anwendbaren therapeutischen zubereitung.
DE69804791D1 (de) Anlage zur erzeugung von ozoniertem wasser
DK0528494T3 (da) Katalysatorsammensætninger omfattende en modificeret zeolit af Y-typen
ATE321775T1 (de) Reinigung von fibrinogen aus milch durch den einsatz von kationenaustauschchromatographie
ATE256695T1 (de) Verfahren zur herstellung von pharmazeutisch annehmbaren salzen des (ss,rs)-s-adenosyl-l- menthionin
ATE194167T1 (de) Ein prozess für die herstellung von faktor ix biologischen ursprungs
DE69421609D1 (de) Hypochloritbleichmittelzusammensetzungen
BR9002873A (pt) Composicao aquosa de condicionamento de cabelo e processo para aperfeicoar a elasticidade do cabelo
DE69627064D1 (de) Behandlung von Fasern
ATE304093T1 (de) Knotenverbinder zum befestigen einer montageschiene auf stoss an einer anderen montageschiene
BR0016668A (pt) Processo para a preparação de n-fosfonometilglicina, processo para a preparação de um composto fosfono, composto fosfono, e, intermediário
ATE291569T1 (de) Verfahren zur herstellung von dnda
DE59803194D1 (de) Verfahren zur herstellung von 1,3-disubstituierten 2-nitroguanidinen
DE59801815D1 (de) Verfahren zur herstellung von 1,2-dichlorethan durch oxichlorierung
BR0007960A (pt) Tablete detergente revestido
DE69611924T2 (de) Verfahren zur herstellung von mangansulfid
ATE190647T1 (de) Hypochloritbleichmittelzusammensetzung

Legal Events

Date Code Title Description
8364 No opposition during term of opposition